TNF Inhibitor denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tnf inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies TNF Inhibitors as Not FDA-Approved

A "not FDA-approved" denial from Blue Cross Blue Shield in the context of a TNF inhibitor typically arises in one of two scenarios: (1) the drug is being used for an indication — a diagnosis or condition — that is not listed in the FDA-approved prescribing label (an "off-label" use), or (2) there is a documentation or coding error that made the claim appear as though it involved an unapproved product. Understanding which scenario applies is the essential first step before appealing.

## Why This Denial Is Appealable

Off-label use of FDA-approved drugs is medically and legally recognized. Most state laws and many federal guidelines require insurers to cover off-label uses of FDA-approved drugs when supported by peer-reviewed evidence listed in recognized drug compendia (such as the NCCN Drugs & Biologics Compendium, Clinical Pharmacology, or Micromedex). If your use is compendia-listed, BCBS is generally required to cover it. If there is a coding error, the path is correction and resubmission rather than a formal appeal.

## Federal Appeal Rights

• Internal appeal: Contest the denial under ERISA §503 or your state's insurance code. Provide evidence that the use is FDA-approved for your diagnosis, or that it is supported by an accepted drug compendium.
• External review (ACA §2719): If BCBS upholds the denial internally, an independent external reviewer can assess whether the denial was consistent with generally accepted standards of medical practice and applicable law.
• Expedited review: Available if delay poses a risk to your health.

## Documentation to Gather

1. Confirm FDA approval status: Verify with your prescriber or pharmacist that the specific TNF inhibitor you were prescribed IS FDA-approved for your exact diagnosis. Obtain a copy of the relevant section of the FDA-approved prescribing label. 2. Compendium listing: Ask your prescriber or pharmacist to confirm whether your specific use is listed in a major drug compendium (NCCN, Micromedex, Clinical Pharmacology). A printout of the relevant compendium entry is powerful appeal evidence. 3. Diagnosis coding review: Confirm that the diagnosis code (ICD-10) on the claim matches the approved indication. Miscoding is a common cause of these denials and can be corrected without a formal appeal. 4. Prescriber letter: A letter explaining the clinical basis for the drug choice, its established use in peer-reviewed literature, and its compendium status. 5. BCBS off-label policy: Request the plan's off-label drug policy to understand exactly what evidence standard they apply.

## Criteria-Mapping Structure

| Denial Basis | Your Rebuttal Evidence | |---|---| | Indication not FDA-labeled | [FDA label section confirming approved indication, OR compendium entry for off-label use] | | Use not in recognized compendium | [Compendium name, listing confirmation] | | Coding mismatch | [Correct ICD-10 code, corrected claim if applicable] |

Many "not FDA-approved" denials for established biologics are resolved quickly once the correct documentation is submitted, particularly when the FDA label or a major compendium clearly supports the use.